NEW YORK, NY / ACCESSWIRE / August 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of The Chemours Company ("The Chemours Company") (NYSE:CC) concerning possible violations of federal securities laws. Chemours issued a press release on August 1, 2024, reporting its financial results for the second quarter of 2024.
LOS ANGELES, CA / ACCESSWIRE / August 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of The Chemours Company ("Chemours" or "the Company") (NYSE:CC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
NEW YORK, NY / ACCESSWIRE / August 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of The Chemours Company ("The Chemours Company") (NYSE:CC) concerning possible violations of federal securities laws. Chemours issued a press release on August 1, 2024, reporting its financial results for the second quarter of 2024.
NEW YORK, NY / ACCESSWIRE / August 9, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of The Chemours Company ("Chemours" or "the Company") (NYSE:CC). Investors who purchased Chemours securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CC.
NEW YORK, NY / ACCESSWIRE / August 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of The Chemours Company ("The Chemours Company") (NYSE:CC) concerning possible violations of federal securities laws. Chemours issued a press release on August 1, 2024, reporting its financial results for the second quarter of 2024.
NEW YORK, NY / ACCESSWIRE / August 8, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of The Chemours Company ("Chemours" or "the Company") (NYSE:CC). Investors who purchased Chemours securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CC.
NEW YORK, NY / ACCESSWIRE / August 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of The Chemours Company ("The Chemours Company") (NYSE:CC) concerning possible violations of federal securities laws. Chemours issued a press release on August 1, 2024, reporting its financial results for the second quarter of 2024.
NEW YORK, NY / ACCESSWIRE / August 7, 2024 / 2024 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of The Chemours Company ("Chemours" or the "Company") (NYSE:CC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Chemours' (CC) earnings miss estimates in the second quarter due to lower selling prices.
The Chemours Company (NYSE:CC ) Q2 2024 Earnings Conference Call August 2, 2024 8:00 AM ET Company Participants Brandon Ontjes - VP of IR Denise Dignam - President and CEO Shane Hostetter - SVP, CFO & Principal Accounting Officer Conference Call Participants John McNulty - BMO Capital Markets Mike Leithead - Barclays John Roberts - Mizuho Josh Spector - UBS Financial Hassan Ahmed - Alembic Global Advisors Laurence Alexander - Jefferies Arun Viswanathan - RBC Capital Markets Vincent Andrews - Morgan Stanley John McNulty - BMO Capital Markets Operator Good morning. My name is Regina and I will be your conference operator today.
The headline numbers for Chemours (CC) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Chemours (CC) came out with quarterly earnings of $0.38 per share, missing the Zacks Consensus Estimate of $0.66 per share. This compares to earnings of $1.10 per share a year ago.